<DOC>
	<DOC>NCT00681629</DOC>
	<brief_summary>The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month</brief_summary>
	<brief_title>Schizophrenic Patients in Integrated Care</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients with baseline SWNK &lt;=70 Provision of signed informed consent Outpatients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAMD cut off score of 20 points Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation Patients who pose an imminent risk of suicide or danger to self or others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Integrated Care</keyword>
	<keyword>Quetiapine</keyword>
</DOC>